Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
General Internal Medicine
•
Rheumatology
•
Systemic sclerosis
•
Scleroderma
•
Eosinophilic Fasciitis
How do you approach initial steroid dosing in patients with eosinophilic fasciitis?
When do you consider adding steroid sparing agents?
Related Questions
In patients with diffuse scleroderma and symptomatic lower extremity venous insufficiency, would you recommend treatment with endovenous laser/ablation?
How do you approach the significance of +RNP III antibody in a patient with positive ANA but no other signs or symptoms of systemic sclerosis?
What considerations do you take when using prednisone in patients with systemic sclerosis?
If a patient has progression of scleroderma-ILD on MMF alone, and you are planning to start tocilizumab, would you continue MMF at a lower dose to maintain skin softening?
How do you envision incorporating CAR-T therapy into your clinical practice?
What are some important considerations for use of ACE inhibition in scleroderma renal crisis patients who require dialysis?
How would you approach a patient with anti-scl70 ab positive sine scleroderma complicated by ILD who also has seropositive RA with active arthritis?
What treatment regimen would you recommend for a patient with biopsy-proven giant cell arteritis and diffuse cutaneous systemic sclerosis?
Would you consider altering immunosuppression in a patient with systemic sclerosis (already on systemic immunosuppression for interstitial lung disease) who has more recently been noted to have LV diastolic dysfunction with some reduction in EF in the absence of other worsening symptoms?
Do you generally utilize calcium channel blockers on an as needed basis for patients with Raynaud's phenomenon?